Incidence of Cytomegalovirus Infections after Standard of Care CD19 CAR-T cell Therapy: A Retrospective Analysis. (TCT-ASTCT-CIBMTR 2026) - Jan 8, 2026 - Abstract #219; 757; Pres time: Feb 5, 2026; 06:30 PM - 08:00 PM; Location: Hall AB (Salt Palace Convention Center); "Methods : We conducted a single-center retrospective study of patients ≥18 years with B-cell lymphomas who received standard-of-care CAR-T therapy (axicabtagene ciloleucel (Yescarta), brexucabtagene autoleucel (Tecartus), lisocabtagene maraleucel (Breyanzi), or tisagenlecleucel (Kymriah)) between January 2023 and October 2024 at MD Anderson Cancer Center. CMV viremia is increasingly recognized as a complication following CAR-T therapy, particularly with Yescarta and Tecartus. The effect of CMV viremia on CAR T cell morbidity and mortality will need further exploration. Prophylactic strategies such as letermovir can be considered."
CAR T-Cell Therapy • Retrospective data • B Cell Lymphoma • Cytomegalovirus Infection • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Infectious Disease • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin's Lymphoma
|
|
Mousa Thalji, MD 1; Sairah Ahmed, MD 2; Sattva S. Neelapu, MD 2; Veronica Leautaud, PhD 3; Amy A. Ayers, MPH 2; Paolo Strati, MD 2; Ranjit Nair, MD 3; Amanda L. Olson, MD 4; Roy F. Chemaly, MD, MPH, FIDSA, FACP 5; Richard E. Champlin, MD 4; Fareed Khawaja, MD 6; George L. Chen, MD 4
|